BT Bidco

Biora Therapeutics (operating as BT Bidco Inc.) is a clinical-stage biotechnology company specializing in the development of smart, ingestible drug-delivery platforms. The company's core technologies, NaviCap™ and BioJet™, are designed to transform the delivery of therapeutics for chronic diseases by providing targeted or systemic oral delivery of drugs that typically require injections. NaviCap is an ingestible capsule that delivers therapeutics directly to the gastrointestinal tract, while BioJet is an oral autoinjector for the systemic delivery of large molecules like monoclonal antibodies and peptides. The company's lead program, BT-600, utilizes the NaviCap platform to deliver tofacitinib for the treatment of ulcerative colitis and is currently in Phase 1 clinical development. Following a corporate restructuring in 2025, the company continues to advance its pipeline of oral biotherapeutics to improve patient outcomes and treatment adherence.